Laekna HK$791 million IPO
We advised Laekna on its IPO and HKEX listing
Davis Polk advised Laekna, Inc. in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance on Regulation S. The net proceeds from the offering amounted to approximately HK$791 million.
Founded in 2016, Laekna, Inc. is a science-driven, clinical-stage biotechnology company. It has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials and has initiated one clinical trial and another five clinical trials for its core products LAE002 and LAE001. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address medical needs in the standard of care (SOC)-resistant cancers.
The Davis Polk corporate team included partners Xuelin (Steve) Wang, Yang Chu and Jason Xu, associates Jenny Ho and Michelle Chow and registered foreign lawyers Wentian Xie and Haiyang Zhao. Members of the Davis Polk team are based in the Hong Kong and Beijing offices.
Related Posts
Yizhu Technology Completes Multi-Hundred-Million RMB Financing to Drive AI Chip Innovation （October 15, 2024)
Yizhu Technology announced completion of multi-hundred-million RMB financing led by a renowned overseas fund with participation from Shengshi Technology and Xingzhi Capital. The funding will support ongoing development and innovation of AI compute chips and system solutions, focusing on overcoming the “memory wall” and “energy wall” for
Seizing Entrepreneurial Opportunities in Pudong: Embracing the Rise of Returnee Entrepreneurs
From November 9th to 11th, under the guidance of the United Front Work Department of the Shanghai Municipal Committee (Overseas Chinese Affairs Office of the Municipal Government), the “Overseas Chinese Innovation and Entrepreneurship Study Camp” (the 3rd Study Camp for Overseas Chinese Young Science and Technology Entrepreneurs and the 16th Study C
Leto Laboratories Completes Series C Financing of Over 100 Million RMB, Focusing on 0 to 1 Innovative Protein Design and Manufacturing Platform Construction
Leto Laboratories announced the completion of its Series C financing round with a funding size of over 100 million RMB. This round of financing was led by Zhongguancun Science City Corporation and followed by Infiniti Capital and HB Ventures. The round was mainly used for the clinical research of LTC004, a new-generation anti-tumor cytokine class […]
” E-Tronic(Guangzhou) Technology” completes Series A financing led by Infinity Capital
E-Tronic(Guangzhou)Technology Co.，Ltd., a provider of power semiconductors and system solutions for new energy vehicles, has completed its Series A financing with a cumulative amount of over 100 million RMB. This round of financing was led by Infinity Capital, with additional investment from old shareholders Zhongnan Venture Capital and Guangzhou Development